Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Publications

Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

PMID: 24744161
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1. Epub 2014 Apr 18.
Impact factor:
Publication type: Paper in international publication
Authors: Aguirre, Elena; Benhadji, Karim A; Callies, Sophie; Garcia, Margarita; Gil-Martin, Marta; Llombart, Antonio; Morales, Serafin; Oaknin, Ana; Salazar, Ramon; Wickremsinhe, Enaksha R et al.
DOI: 10.1007/s00280-014-2457-1

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 24652201
Journal: INVEST NEW DRUG
Year: 2014
Reference: Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
Impact factor: 2.927
Publication type: Paper in international publication
Authors: Brana, Irene, Siu, Lillian L, De Jonge, Maja J, Homji, Natasha, Mills, David, Di Tomaso, Emmanuelle, Sarr, Celine, Trandafir, Lucia, Massacesi, Cristian, Eskens, Ferry et al.
DOI: 10.1007/s10637-014-0082-9

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 24652201
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2014
Reference: Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
Impact factor:
Publication type: Paper in international publication
Authors: Bendell, Johanna C; Brana, Irene; De Jonge, Maja J; Di Tomaso, Emmanuelle; Eskens, Ferry; Homji, Natasha; Massacesi, Cristian; Mills, David; Rodon, Jordi; Sarr, Celine et al.
DOI: 10.1007/s10637-014-0082-9

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

PMID: 24496004
Journal: J THORAC ONCOL
Year: 2014
Reference: J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
Impact factor: 5.8
Publication type: Paper in international publication
Authors: Felip, Enriqueta, Martinez, Pablo, Janne, Pasi A, Cohen, Roger B, Laird, A Douglas, Mace, Sandrine, Engelman, Jeffrey A, Ruiz-Soto, Rodrigo, Rockich, Kevin, Xu, Jianbo et al.
DOI: 10.1097/JTO.0000000000000088

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

PMID: 24496004
Journal: Journal of Thoracic Oncology
Year: 2014
Reference: J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
Impact factor:
Publication type: Paper in international publication
Authors: Cohen, Roger B; Engelman, Jeffrey A; Felip, Enriqueta; Janne, Pasi A; Laird, A Douglas; Mace, Sandrine; Martinez, Pablo; Rockich, Kevin; Ruiz-Soto, Rodrigo; Shapiro, Geoffrey I et al.
DOI: 10.1097/JTO.0000000000000088

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

PMID: 24583798
Journal: CLIN CANCER RES
Year: 2014
Reference: Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.
Impact factor: 8.193
Publication type: Paper in international publication
Authors: Papadopoulos, Kyriakos P, Tabernero, Josep, Markman, Ben, Patnaik, Amita, Tolcher, Anthony W, Baselga, Jose, Shi, Weiliang, Egile, Coumaran, Ruiz-Soto, Rodrigo, Laird, A Douglas et al.
DOI: 10.1158/1078-0432.CCR-13-2403

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

PMID: 24583798
Journal: CLINICAL CANCER RESEARCH
Year: 2014
Reference: Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.
Impact factor:
Publication type: Paper in international publication
Authors: Baselga, Jose; Egile, Coumaran; Laird, A Douglas; Lorusso, Patricia M; Markman, Ben; Miles, Dale; Papadopoulos, Kyriakos P; Patnaik, Amita; Ruiz-Soto, Rodrigo; Shi, Weiliang et al.
DOI: 10.1158/1078-0432.CCR-13-2403

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

PMID: 25142843
Journal: ONCOLOGIST
Year: 2014
Reference: Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.
Impact factor: 4.54
Publication type: Paper in international publication
Authors: Suarez, Cristina, Bellmunt, Joaquim, Pons, Francesc, Bonfill, Teresa, Beltran, Marta, Moya, Irene, Galtes, Susana, Albanell, Joan, Carles, Joan, Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2014-0072

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

PMID: 25142843
Journal: ONCOLOGIST
Year: 2014
Reference: Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.
Impact factor:
Publication type: Paper in international publication
Authors: Albanell, Joan; Bellmunt, Joaquim; Beltran, Marta; Bonfill, Teresa; Carles, Joan; Gallardo, Enrique; Galtes, Susana; Moya, Irene; Pons, Francesc; Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2014-0072

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

PMID: 24827126
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
Impact factor: 6.578
Publication type: Paper in international publication
Authors: Balmana, J, Tung, N M, Isakoff, S J, Grana, B, Ryan, P D, Saura, C, Lowe, E S, Frewer, P, Winer, E, Baselga, J et al.
DOI: 10.1093/annonc/mdu187

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

PMID: 24827126
Journal: ANNALS OF ONCOLOGY
Year: 2014
Reference: Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
Impact factor:
Publication type: Paper in international publication
Authors: Balmana, J; Baselga, J; Frewer, P; Garber, J E; Grana, B; Isakoff, S J; Lowe, E S; Ryan, P D; Saura, C; Tung, N M et al.
DOI: 10.1093/annonc/mdu187

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

PMID: 24470511
Journal: CLIN CANCER RES
Year: 2014
Reference: Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.
Impact factor: 8.193
Publication type: Clinical Trials
Authors: Di Tomaso, Emmanuelle, Saura, Cristina, Bendell, Johanna, Jerusalem, Guy, Su, Shaun, Ru, Qinhua, De Buck, Stefan, Mills, David, Ruquet, Sophie, Bosch, Ana et al.
DOI: 10.1158/1078-0432.CCR-13-1070

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

PMID: 24470511
Journal: CLINICAL CANCER RESEARCH
Year: 2014
Reference: Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.
Impact factor:
Publication type: Clinical Trials
Authors: Baselga, Jose; Beck, Joseph T; Bendell, Johanna; Bosch, Ana; De Buck, Stefan; Di Tomaso, Emmanuelle; Dirix, Luc; Hirawat, Samit; Jerusalem, Guy; Massacesi, Cristian et al.
DOI: 10.1158/1078-0432.CCR-13-1070

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

PMID: 24570330
Journal: CANCER CHEMOTH PHARM
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.
Impact factor: 2.571
Publication type: Paper in international publication
Authors: Siguero, Mariano, Castellano, Daniel E, Bellmunt, Joaquim, Maroto, Jose Pablo, Font-Pous, Albert, Morales-Barrera, Rafael, Ghanem, Ismael, Suarez, Cristina, Martin Lorente, Cristina, Etxaniz, Olatz et al.
DOI: 10.1007/s00280-014-2419-7

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

PMID: 24570330
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.
Impact factor:
Publication type: Paper in international publication
Authors: Alfaro, Vicente; Bellmunt, Joaquim; Capdevila, Laia; Carles, Joan; Castellano, Daniel E; Coronado, Cinthya; Etxaniz, Olatz; Fernandez-Teruel, Carlos; Font-Pous, Albert; Ghanem, Ismael et al.
DOI: 10.1007/s00280-014-2419-7

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

PMID: 25270629
Journal: STROKE
Year: 2014
Reference: Stroke. 2014 Nov;45(11):3304-10. doi: 10.1161/STROKEAHA.114.005835. Epub 2014 Sep 30.
Impact factor: 6.018
Publication type: Clinical Trials
Authors: Urfer, Roman, Moebius, Hans J, Skoloudik, David, Santamarina, Estevo, Sato, Wakao, Mita, Shiro, Muir, Keith W et al.
DOI: 10.1161/STROKEAHA.114.005835

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

PMID: 25270629
Journal: STROKE
Year: 2014
Reference: Stroke. 2014 Nov;45(11):3304-10. doi: 10.1161/STROKEAHA.114.005835. Epub 2014 Sep 30.
Impact factor:
Publication type: Clinical Trials
Authors: Mita, Shiro; Moebius, Hans J; Muir, Keith W; Santamarina, Estevo; Sato, Wakao; Skoloudik, David; Urfer, Roman et al.
DOI: 10.1161/STROKEAHA.114.005835

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

PMID: 24081577
Journal: ANN HEMATOL
Year: 2014
Reference: Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.
Impact factor: 2.396
Publication type: Clinical Trials
Authors: Martinez-Cuadron, David, Montesinos, Pau, Oriol, Albert, Salamero, Olga, Vidriales, Belen, Bergua, Juan, Herrera, Pilar, Vives, Susanna, Sanz, Jaime, Carpio, Cecilia et al.
DOI: 10.1007/s00277-013-1914-y

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

PMID: 24081577
Journal: ANNALS OF HEMATOLOGY
Year: 2014
Reference: Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.
Impact factor:
Publication type: Clinical Trials
Authors: Bergua, Juan; Carpio, Cecilia; Herrera, Pilar; Martinez-Cuadron, David; Montesinos, Pau; Moscardo, Federico; Oriol, Albert; Rodriguez-Veiga, Rebeca; Salamero, Olga; Sanz, Jaime et al.
DOI: 10.1007/s00277-013-1914-y

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 24401928
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.
Impact factor: 6.578
Publication type: Clinical Trials
Authors: Baselga, J, Manikhas, A, Cortes, J, Llombart, A, Roman, L, Semiglazov, V F, Byakhov, M, Lokanatha, D, Forenza, S, Goldfarb, R H et al.
DOI: 10.1093/annonc/mdt543

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 24401928
Journal: ANNALS OF ONCOLOGY
Year: 2014
Reference: Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.
Impact factor:
Publication type: Clinical Trials
Authors: Azarnia, N; Baselga, J; Byakhov, M; Cortes, J; Forenza, S; Goldfarb, R H; Hudis, C A; Llombart, A; Lokanatha, D; Manikhas, A et al.
DOI: 10.1093/annonc/mdt543

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

PMID: 25193991
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5.
Impact factor: 6.578
Publication type: Clinical Trials
Authors: Robert, R, D'Incalci, M, Zucchetti, M, Camboni, M G, Tabernero, J, Saba, C, Dubois, F, Allen, A, Litten, J, Soria, J-C et al.
DOI: 10.1093/annonc/mdu390

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

PMID: 25193991
Journal: ANNALS OF ONCOLOGY
Year: 2014
Reference: Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5.
Impact factor:
Publication type: Clinical Trials
Authors: Adamo, B; Allen, A; Andre, F; Bahleda, R; Camboni, M G; Cereda, R; D'Incalci, M; DeBraud, F; Delmonte, A; Dientsmann, R et al.
DOI: 10.1093/annonc/mdu390

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

PMID: 24997153
Journal: HAEMATOLOGICA
Year: 2014
Reference: Haematologica. 2014 Oct;99(10):1632-7. doi: 10.3324/haematol.2014.105908. Epub 2014 Jul 4.
Impact factor: 5.868
Publication type: Clinical guide
Authors: Valcarcel, David, Jarque, Isidro, Jimenez, Santiago, Rovira, Montserrat, Lopez, Javier, Hernandez, Dolores, Vallejo, Carlos, Batlle, Montserrat, Vazquez, Lourdes, Solano, Carlos et al.
DOI: 10.3324/haematol.2014.105908